Abstract
Monoclonal antibodies (mAbs) and antibody fragments represent the most important biopharmaceutical products today. Because full length antibodies are glycosylated, mammalian cells, which allow human-like N-glycosylation, are currently used for their production. However, mammalian cells have several drawbacks when it comes to bioprocessing and scale-up, resulting in long processing times and elevated costs. By contrast, antibody fragments, that are not glycosylated but still exhibit antigen binding properties, can be produced in microbial organisms, which are easy to manipulate and cultivate. In this review, we summarize recent advances in the expression systems, strain engineering, and production processes for the three main microbials used in antibody and antibody fragment production, namely Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli.
Original language | English |
---|---|
Pages (from-to) | 54-60 |
Journal | Trends in Biotechnology |
Volume | 32 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2014 |
Fields of Expertise
- Human- & Biotechnology
Treatment code (Nähere Zuordnung)
- Review